Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Non-Current Liabilities (2016 - 2025)

Rocket Pharmaceuticals' Total Non-Current Liabilities history spans 10 years, with the latest figure at $52.2 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 17.62% year-over-year to $52.2 million; the TTM value through Dec 2025 reached $52.2 million, down 17.62%, while the annual FY2025 figure was $52.2 million, 17.62% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $52.2 million at Rocket Pharmaceuticals, down from $53.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $96.4 million in Q1 2021 and bottomed at $42.2 million in Q4 2021.
  • The 5-year median for Total Non-Current Liabilities is $55.9 million (2023), against an average of $56.7 million.
  • The largest YoY upside for Total Non-Current Liabilities was 41.0% in 2022 against a maximum downside of 55.93% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $42.2 million in 2021, then soared by 41.0% to $59.5 million in 2022, then rose by 18.99% to $70.8 million in 2023, then decreased by 10.6% to $63.3 million in 2024, then decreased by 17.62% to $52.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Total Non-Current Liabilities are $52.2 million (Q4 2025), $53.3 million (Q3 2025), and $65.7 million (Q2 2025).